Cilgavimab Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The SARS-CoV-2 spike glycoprotein drives viral attachment and entry and is a primary antigen for neutralization and infection research. Provided as an unconjugated, non-therapeutic analog of cilgavimab, this human IgG1-kappa recombinant antibody is intended strictly for research use (RUO). It is an ultra-pure, low-endotoxin preparation meeting in vivo standards and produced in scalable milligram-to-gram quantities for heavy-usage, high-throughput virology laboratories. Suitable applications include neutralization and functional assays, spike-binding characterization, in vitro screening and preclinical coronavirus models, with dependable lot-to-lot consistency. Supplied low in endotoxin and built to in vivo standards, it scales from milligram to gram quantities for bulk, reagent-intensive workflows.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks